GET DAILY SIGNALSCardinal Health (CAH), Cencora (COR), and McKesson (MCK): Weighing the Top U.S. Pharma Distributors
Key Takeaways
- CAH, COR, and MCK are the three largest U.S. pharmaceutical distributors, competing on scale, specialty services, and oncology, yet diverging in recent market momentum.
- Tickeron AI Verdict: CAH — Cardinal Health currently presents the most consistent blend of upward price trend, earnings momentum, and clarity of forward guidance among the three.
- MCK is the scale leader with the lowest volatility, but its premium valuation and an in-progress Medical-Surgical separation introduce execution uncertainty.
- COR is investing heavily in specialty and oncology through acquisitions, yet has lagged peers on a year-to-date basis amid margin and transaction-related headwinds.
- All three operate low-margin, high-volume distribution models, meaning relative performance often hinges on profit growth and capital deployment rather than revenue alone.
Why These Three Distributors Matter
Cardinal Health, Cencora, and McKesson form the backbone of U.S. pharmaceutical distribution, channeling branded, generic, specialty, and biosimilar medicines to pharmacies, hospitals, and clinics. Investors and traders often evaluate these three names together because they share a defensive, economically resilient business profile while offering distinct growth drivers, valuations, and risk profiles. This stock comparison examines recent market activity, business positioning, and relative performance across the trio. It is especially relevant for those seeking healthcare exposure that balances steady cash generation with differentiated growth in specialty, oncology, and logistics services, and for readers weighing which of the three may offer the strongest risk-adjusted setup in the current environment.
Cardinal Health (CAH) Overview and Recent Performance
CAH, or Cardinal Health, is a Dublin, Ohio-based healthcare distributor and manufacturer of medical products. Its Pharmaceutical and Specialty Solutions segment is the core revenue engine, complemented by a global medical products business and a faster-growing "Other" portfolio spanning nuclear and precision health, at-home solutions, and logistics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
In recent market activity, CAH has been a standout. For its fiscal year ended June 30, 2026, revenue rose 14% to roughly $254 billion, while adjusted diluted earnings per share (EPS, or the profit allocated to each share) climbed 37% to $11.26. Management issued fiscal 2027 adjusted EPS guidance of $12.40 to $12.60, implying 13% to 15% growth, supported by tuck-in acquisitions and operational investment. The company also completed $1.4 billion in buybacks and authorized an additional $5 billion. Shares reached a fresh 52-week high in recent weeks, reflecting sustained upward momentum and multiple consecutive quarters of earnings beats, though the low gross margin (near 4%) underscores the thin-margin nature of its distribution model.
Cencora (COR) Overview and Recent Performance
COR, or Cencora (formerly AmerisourceBergen), is a Conshohocken, Pennsylvania-based pharmaceutical distributor with a large U.S. Healthcare Solutions segment and a growing international footprint. The company has prioritized specialty distribution and provider services, most notably through its February 2026 acquisition of OneOncology, a network of community oncology practices.
Recent results have been solid but have not translated into the same share-price momentum as peers. In its fiscal third quarter, revenue increased about 5% to $84.75 billion, and adjusted EPS of $4.48 modestly exceeded consensus. Management raised full-year fiscal 2026 adjusted EPS guidance to a range of $17.75 to $17.95. However, sentiment has been tempered by factors including manufacturer list-price reductions, a prior oncology customer loss, and the planned MWI–Covetrus animal-health combination, which management flagged as a potential fiscal 2027 earnings headwind. On a year-to-date basis, COR shares have trailed the broader market, even as analysts remain broadly constructive on its specialty-driven growth and capital returns.
McKesson (MCK) Overview and Recent Performance
MCK, or McKesson, is an Irving, Texas-based healthcare services company and the largest of the three by revenue and market capitalization. It operates across North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions segments.
McKesson delivered the group's strongest headline growth in its fiscal 2026, with revenue up about 12% to $403 billion and diluted EPS rising to $38.38. Its oncology and multispecialty franchise expanded rapidly, and GLP-1 (glucagon-like peptide-1, a class of diabetes and weight-management medicines) distribution revenue reached roughly $53 billion for the year. Management guided fiscal 2027 adjusted EPS to $43.80 to $44.60 and reaffirmed a 13% to 16% long-term EPS growth target. The company is also executing a Medical-Surgical Solutions separation, backed by a $1.25 billion minority investment from Apollo. With a beta near 0.3, MCK is the least volatile of the trio, though its higher multiple and the separation's execution risk are key watchpoints.
Head-to-Head Comparison
While all three companies share a common distribution core, their growth profiles and risk characteristics differ meaningfully. MCK is the scale and diversification leader, with the deepest oncology network and the strongest GLP-1 exposure, but it trades at a premium valuation and carries separation-related execution risk. COR is the most acquisition-driven, betting on specialty and oncology services for margin expansion, yet it faces near-term transaction headwinds and has shown weaker relative share-price performance. CAH sits in the middle on size but has generated the strongest recent earnings momentum and clearest near-term guidance, with improving profitability across its medical products and higher-growth segments. From what I see, after reviewing the data, CAH's positioning looks particularly balanced right now.
On valuation, all three carry low price-to-sales multiples reflective of thin distribution margins, but their forward earnings multiples differ, with MCK generally commanding the richest multiple. On sentiment, CAH has trended toward new highs while COR has consolidated. Risk factors for the group include drug-pricing policy, generic deflation, customer concentration, and margin pressure from low-margin specialty volumes, though each company's defensive demand profile provides a degree of stability through economic cycles.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, catalyst clarity, and relative positioning, Tickeron's AI would currently lean toward CAH. Cardinal Health combines a confirmed uptrend with consecutive earnings beats, a fresh 52-week high, and a well-defined double-digit EPS growth outlook for fiscal 2027, factors that algorithmic models often weight favorably. While MCK offers superior scale and lower volatility and COR presents longer-term specialty optionality, CAH's recent momentum and comparatively cleaner near-term catalyst path give it the edge in the current setup. This assessment is probabilistic rather than definitive and reflects current market conditions rather than a fixed, permanent ranking.
Exploring AI Trading Bots for Sector Insights
One tool I turn to regularly when comparing names like these is Tickeron’s AI Trading Bots. The platform lets me review how different systematic strategies have performed on healthcare distributors, adding a quantitative layer to the fundamental and valuation work. It has helped me spot patterns in momentum and risk that are not always obvious from earnings releases alone, and I find it especially practical for keeping an eye on relative strength across the group.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CAH turns positive, indicating new upward trend
CAH saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 65 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 47 cases where CAH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
CAH moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CAH crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 58%.
Following a +2.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAH advanced for three days, in 264 of 396 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 188 of 310 cases where CAH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for CAH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 22 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Moving Average Convergence Divergence Histogram (MACD) for CAH turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 26 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
CAH broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. CAH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-20.428) is normal, around the industry mean (12.613). CAH has a moderately high P/E Ratio (34.983) as compared to the industry average of (10.633). Projected Growth (PEG Ratio) (1.105) is also within normal values, averaging (2.016). Dividend Yield (0.008) settles around the average of (0.138) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of pharmaceuticals, medical, surgical and laboratory supplies as well as develops drug delivery systems
Industry MedicalDistributors
Advertisement